ARGX vs ELV
argenx SE vs Elevance Health — AI-powered side-by-side comparison
VS
ELV
Elevance Health
69
Buy
| Metric | ARGX | ELV |
|---|
| AI Score |
68
|
69
|
| Price |
$851.51
|
$400.25
|
| P/E Ratio |
30.62×
|
17.79×
|
| ROE |
17.6%
|
12.9%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
89.9%
|
39.0%
|
| Debt / Equity |
0.01×
|
0.69×
|
| Dividend Yield |
0.0%
|
1.7%
|
| RSI (14) |
41.5
|
62.8
|
| Beta |
-0.022
|
0.692
|
| Expected Upside |
+0.0%
|
+0.5%
|
AI Committee View
Current Innellis committee reasoning for ARGX versus ELV.
ELV leads by 1 points.
ELV scores 69/100 (Buy) versus ARGX at 68/100 (Buy).
ARGX Committee View
50% agreement
6 analysts
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull Case
- ROE of 22.4% shows genuine earnings power backing the valuation — Value
- Revenue growing 71.3% YoY -- genuine top-line momentum — Growth
- EPS growing 95.7% YoY — Growth
Bear Case
- Price-to-book of 6.9x prices in significant intangible value — Value
- MACD histogram negative -- bearish momentum — Technical
ELV Committee View
80% agreement
5 analysts
The primary driver is vix regime is low -- calm backdrop supports risk-taking. The main limiting factor is growth rate is decelerating quarter over quarter -- the trend line matters more than the level. The committee is constructive but not yet at full conviction.
Bull Case
- 4 consecutive earnings beats -- consistent execution — Growth
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
Bear Case
- Growth rate is decelerating quarter over quarter -- the trend line matters more than the level — Growth